EP0360390A1 — Spirolactam derivatives
Assigned to Glaxo Group Ltd · Expires 1990-03-28 · 36y expired
What this patent protects
These are described spirolactam derivatives of formulae (Ia) and (Ib) wherein R represents a hydrogen atom or a conventional nitrogen protecting group; R¹ represents a hydrogen atom or a conventional carboxyl protecting group or activating group; R² represents the side c…
USPTO Abstract
These are described spirolactam derivatives of formulae (Ia) and (Ib) wherein R represents a hydrogen atom or a conventional nitrogen protecting group; R¹ represents a hydrogen atom or a conventional carboxyl protecting group or activating group; R² represents the side chain of any naturally occurring amino acid; m represents 1 or 2; n representss 1 or 2; the configuration at * may be (R) or (S) or a mixture thereof; with the proviso that when R represents the nitrogen protecting group R³-CO(O)- (where R³ represents (CH₃)₃C-), the group -CO₂R¹ represents the protected carboxy group -CO₂CH₃, m is 1 and n is 1 in the compounds of formula (Ib); R² may not represent an arylmethyl group; and solvates or acid addition salts thereof. These derivatives are of value in the preparation of spirolactam compounds which, depending on their stereochemistry, are either antagonists or agonists of substance P, and as such have a variety of therapeutic properties.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.